GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardio Diagnostics Holdings Inc (NAS:CDIO) » Definitions » Piotroski F-Score

CDIO (Cardio Diagnostics Holdings) Piotroski F-Score : N/A (As of Mar. 04, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Cardio Diagnostics Holdings Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Cardio Diagnostics Holdings has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Cardio Diagnostics Holdings's Piotroski F-Score or its related term are showing as below:

During the past 4 years, the highest Piotroski F-Score of Cardio Diagnostics Holdings was 4. The lowest was 3. And the median was 4.


Cardio Diagnostics Holdings Piotroski F-Score Historical Data

The historical data trend for Cardio Diagnostics Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardio Diagnostics Holdings Piotroski F-Score Chart

Cardio Diagnostics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A N/A 4.00

Cardio Diagnostics Holdings Quarterly Data
Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 4.00 4.00 3.00 N/A

Competitive Comparison of Cardio Diagnostics Holdings's Piotroski F-Score

For the Biotechnology subindustry, Cardio Diagnostics Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardio Diagnostics Holdings's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Cardio Diagnostics Holdings's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was -1.389 + -4.164 + -1.288 + -1.413 = $-8.25 Mil.
Cash Flow from Operations was -1.686 + -1.233 + -1.21 + -1.157 = $-5.29 Mil.
Revenue was 0.005 + 0.016 + 0.008 + 0.007 = $0.04 Mil.
Gross Profit was 0.005 + 0.016 + 0.008 + 0.007 = $0.04 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(5.963 + 4.462 + 4.328 + 3.997 + 4.481) / 5 = $4.6462 Mil.
Total Assets at the begining of this year (Sep23) was $5.96 Mil.
Long-Term Debt & Capital Lease Obligation was $0.49 Mil.
Total Current Assets was $2.63 Mil.
Total Current Liabilities was $0.31 Mil.
Net Income was -2.378 + -1.033 + -4.023 + -1.932 = $-9.37 Mil.

Revenue was 0.001 + 0 + 0.002 + 0.01 = $0.01 Mil.
Gross Profit was 0.001 + 0 + 0.002 + 0.01 = $0.01 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(0 + 6.249 + 8.552 + 6.757 + 5.963) / 5 = $6.88025 Mil.
Total Assets at the begining of last year (Sep22) was $0.00 Mil.
Long-Term Debt & Capital Lease Obligation was $0.72 Mil.
Total Current Assets was $4.52 Mil.
Total Current Liabilities was $2.96 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Cardio Diagnostics Holdings's current Net Income (TTM) was -8.25. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Cardio Diagnostics Holdings's current Cash Flow from Operations (TTM) was -5.29. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=-8.254/5.963
=-1.38420258

ROA (Last Year)=Net Income/Total Assets (Sep22)
=-9.366/0
=

Cardio Diagnostics Holdings's return on assets of this year was -1.38420258. Cardio Diagnostics Holdings's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Cardio Diagnostics Holdings's current Net Income (TTM) was -8.25. Cardio Diagnostics Holdings's current Cash Flow from Operations (TTM) was -5.29. ==> -5.29 > -8.25 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=0.487/4.6462
=0.10481684

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=0.72/6.88025
=0.10464736

Cardio Diagnostics Holdings's gearing of this year was 0.10481684. Cardio Diagnostics Holdings's gearing of last year was 0.10464736. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=2.627/0.309
=8.50161812

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=4.522/2.955
=1.53028765

Cardio Diagnostics Holdings's current ratio of this year was 8.50161812. Cardio Diagnostics Holdings's current ratio of last year was 1.53028765. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Cardio Diagnostics Holdings's number of shares in issue this year was 24.443. Cardio Diagnostics Holdings's number of shares in issue last year was 11.904. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.036/0.036
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.013/0.013
=1

Cardio Diagnostics Holdings's gross margin of this year was 1. Cardio Diagnostics Holdings's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=0.036/5.963
=0.00603723

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=0.013/0
=

Cardio Diagnostics Holdings's asset turnover of this year was 0.00603723. Cardio Diagnostics Holdings's asset turnover of last year was . ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+1+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Cardio Diagnostics Holdings has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Cardio Diagnostics Holdings  (NAS:CDIO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Cardio Diagnostics Holdings Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Cardio Diagnostics Holdings's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardio Diagnostics Holdings Business Description

Traded in Other Exchanges
N/A
Address
311 West Superior Street, Suite 444, Chicago, IL, USA, 60654
Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.
Executives
Robert Philibert director, 10 percent owner, officer: Chief Medical Officer 400 N. ABERDEEN, SUITE 900, CHICAGO IL 60642
Timur Dogan officer: Chief Technology Officer 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Meeshanthini Dogan director, 10 percent owner, officer: Chief Executive Officer 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Warren Hosseinion director C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Elisa V Luqman officer: Chief Financial Officer 37 HARRISON DRIVE, NORTHPORT NY 11768
Khullani Abdullahi officer: VP of Revenue and Strategy 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Brandon Sim director C/O APOLLO MEDICAL HOLDINGS, INC., 1668 S. GARFIELD AVENUE, 3RD FLOOR, ALHAMBRA CA 91801
James Intrater director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Oded Levy director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Stanley K. Lau director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Bd Holding, Inc. 10 percent owner 15 PROSPECT PLACE, IOWA CITY IA 52246
Jonathan Intrater officer: CEO 223 PALMER STREET, PALMER MA 01069
Allan Liu director 1600 PARKWOOD CIRCLE, STE 200, ATLANTA GA 30339-2119
Loren Mortman director 207 EAST 74TH STREET, APARTMENT 10F, NEW YORK NY 10021
Mana Capital Llc 10 percent owner 8 THE GREEN, SUITE A, DOVER DE 19901

Cardio Diagnostics Holdings Headlines

From GuruFocus